IRAK4 Inhibitor
Oncology
PreclinicalStatus Unknown
Key Facts
About Emmaus Life Sciences
Emmaus Life Sciences is a biopharmaceutical company with a mission to develop and commercialize innovative therapies, initially for rare diseases. Its primary achievement is the 2017 FDA approval of Endari (L-glutamine oral powder) for sickle cell disease, establishing a commercial foundation. The company's strategy involves expanding Endari's global footprint, exploring its glutamine-based science in new indications like diverticulosis, and developing a novel cell sheet engineering platform. Recent leadership changes and a focus on financial improvement signal a period of strategic transition.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |